ACTH é o hormônio trófico que estimula a esteroidogênese, promove o crescimento e a manutenção do córtex adrenal. Porém, em linhagens adrenocorticais, assim como em culturas primárias, ACTH inibe a proliferação celular. A linhagem Y-1 de células adrenocorticais de camundongo tem as seguintes respostas a ACTH: aumento da esteroidogênese, arredondamento celular, bloqueio do ciclo celular em G1 e indução dos proto-oncogenes fos e jun. Esta linhagem também responde muito Sem a FGF2, um protótipo da família dos FGFs (Fibroblast Growth Factors) que regula diferenciação e proliferação de diversos tipos celulares, sendo estimulada a transitar pelas fases G0→G1→S do ciclo celular. ACTH antagoniza este efeito de FGF2, inibindo parcialmente a entrada em S induzida por FGF2. Este projeto buscou compreender o papel de c-Myc no controle do ciclo celular de Y-1, com ênfase nos efeitos de ACTH e FGF2 na expressão e atividade de c-Myc. Mostramos que os dois principais controles da expressão de c-Myc em Y-1 são transcrição e degradação da proteína, sendo a concentração de c-Myc o único controle sobre o sistema Myc/Max/Mad, uma vez que a expressão de Max e de Mad-1 , Mad-4 e Mxi é constitutiva em células Y-1. FGF2 induz a expressão de c-Myc através da indução da transcrição e aumento da estabilidade da proteína de forma totalmente dependente da via de Erk-MAPK. ACTH, por outro lado, não interfere com a transcrição de c-myc, mas promove fortemente a degradação da proteína, dependentemente da via de PKA. Utilizando um sistema de transfecção transiente, transfectamos uma quimera da proteína c-Myc com o receptor de estrógeno, MycER. Quando ativada por tamoxifen, a quimera migra para o núcleo e reverte a ação anti-mitogênica de ACTH sobre FGF2, porém, não tem efeito sobre células carenciadas tratadas ou não com ACTH apenas. Em conclusão, o antagonismo entre ACTH e FGF2 no controle da transição G0→G1→S do ciclo celular de Y-1 pode ser explicado pelas suas ações antagônicas sobre a estabilidade da proteína c-Myc. / ACTH is the trophic hormone that stimulates steroidogenesis, promotes growth and maintenance of the adrenal cortex. However, in adrenal cell lines, as well as in primary cultures, ACTH inhibits cell proliferation. ACTH effects on Y-1 cells are: increasing in steroidogenesis, cell rounding, cell cycle blocking in G1 phase and induction of fos and jun proto-oncogenes expression. Y-1 cell line displays a robust response to FGF2, a member from the FGFs family (Fibroblast Growth Factors), which regulates differentiation and proliferation in many cell types, being induced to enter G0→G1→S phases of fhe cell cycle upon FGF2 stimulation. ACTH antagonizes FGF2 effect, partially inhibiting cell cycle progression stimulated by FGF2. This project aimed to investigate c-Myc role in Y-1 cell cycle control, with emphasis on ACTH and FGF2 effects on its expression and activity control. We have shown that there are two main controls of c-Myc expression in Y-1 cells, transcription and protein stability. c-Myc concentration regulates the system Myc/Max/Mad, once Max and also Mad-1, Mad-4 and Mxi expression is constitutive in Y-1 cells. FGF2 induces c-Myc expression by increasing its transcription rate and stabilizing the protein in an Erk-MAPK pathway dependent manner. ACTH, on the other hand, does not control c-myc transcription but promotes a strong degradation of the protein through the PKA pathway. Using a transient transfection system, we were able to express MycER, a chimera of c-Myc and estrogen receptor in Y-1 cells. When activated by tamoxlfen, MycER is translocated to cell nucleus, where it abolishes the anti-mitogenic effect of ACTH over FGF2. However, it has no effect on cell cycle progression of serum starved cells treated or not with ACTH only. In conclusion, their antagonist effects on c-Myc protein stability can explain the antagonist effects of ACTH and FGF2 on the control of G0→G1→S transition of Y-1 cell cycle.

No processo de metástase os movimentos de migração e invasão tem um papel essencial e em ambos a função dos microfilamentos é de grande importância. Neste contexto, o presente trabalho buscoui analisar os efeitos da droga jaspamídeo e após a determinação das concentrações de IC50 para as linhagens HT144 e NGM foram estudados os efeitos da droga. Os tratamentos mostraram que o fármaco atua desorganizando o citoesqueleto de modo dependente de sua concentração. Os ensaios de ferida mostraram diminuição da taxa de fechamento da área livre após os tratamentos e os ensaios de migração com placas de transwell mostraram que os grupos tratados sofrem aumento desse parâmetro. Nos ensaios de invasão com câmara de Boyden o tratamento mostrou-se efetivo apenas para a célula NGM quando tratadas com 75 nM de jaspamídeo e 30 <font face=\"Symbol\">mM de Y-27632. Quanto à migração, a linhagem NGM não completava este processo quando tratada com as concentrações do IC50 e do IC50/2 acrescido de Y-27632 e a linhagem HT144 apresenta aumento deste parâmetro quando tratado com jaspamídeo e 200 <font face=\"Symbol\">mM de NSC23766. / Many signaling ways are involved in metastasis and the cellular migration and invasion are important in this context. The role of microfilaments is essential in mesenchymal and amoeboid migration. In this context, the present work aimed to analyze the effects of the drug jaspamide and. after the determination of the IC50 concentrations for the HT144 and NGM cell lines, the effects of the treatment with jaspamide were studied. The wound assays indicated a decrease in the free area after the treatments, and the migration assays with transwell showed that, after the inoculation with the drug, the cells increased the process of migration. In the invasion assays with Boydens chamber, the treatment with jaspamide was effective only in NGM cells, when they are treated with 75 nM of the drug plus 30 <font face=\"Symbol\">mM of Y-27632. Regarding the migration process, the NGM cell line did not show movement when treated with the IC50 concentration and the IC50/2 concentration plus Y-27632, and the HT144 cell line increases this parameter when treated with jaspamide and 200 <font face=\"Symbol\">mM of NSC23766.

A maioria dos tumores sólidos apresentam características aneuplóides. Porém a relação entre aneuploidia e transformação maligna, ainda não está definida. Nos últimos anos diversas proteínas têm sido descritas como reguladoras de eventos durante a divisão celular, principalmente as relacionadas com a formação do fuso bipolar e segregação equacional dos cromossomos. Neste estudo propomo-nos a analisar os efeitos da interferência em dois pontos críticos da mitose, a segregação cromossômica e a citocinese, em relação à aneuploidia e à instabilidade genética tumoral. Nossos dados mostraram que o tratamento sequencial de Monastrol e Blebistatina determinou o surgimento de fusos mitóticos anormais, amplificação centrossômica, localização ectópica de Aurora A e aumento de micronúcleos. Esta interferência pode levar a um quadro de instabilidade genética e, consequentemente a progressão tumoral, abrindo novas possibilidades para o estudo dos mecanismos moleculares envolvidos na regulação do ponto de checagem mitótico e resistência a quimioterápicos. / Most solid tumors have aneuploid feature. Therefore the relationship between aneuploidy and malignant transformation is not yet understood. In the last years it has been described many proteins involved in regulation of mitosis, mainly those related to bipolar spindle and chromosome segregation. In this work we propose to study the effects of the interference on two mitotic critical points, the chromosome segregation and cytokinesis, in relation to aneuploidy and genetic tumor instability. Our data showed that sequential treatment with Monastrol and Blebbistatin led to abnormal mitotic spindle, centrosome amplification, Aurora A ectopic and micronucleus increased. This interference can lead to genetic instability and may be involved in a tumor progression, opening news possibilities to study the molecular mechanisms involved in regulation the checkpoint mitotic and resistance to chemotherapy found in genetically unstable cells.

Problemas reprodutivos ocorrem no hipo e no hipertireoidismo, mas pouco se conhece a respeito das bases moleculares destas alterações. Avaliou-se o efeito da administração de triiodotironina na atividade do gonadotrofo em ratos Wistar tireoidectomizados. O hipotireoidismo ocasionou elevação no TSH e do LH sérico, aumento do conteúdo do mRNA e redução do conteúdo protéico do LH e do FSH, redução da cauda poli (A), redução da testosterona e do FSH séricos, redução da expressão do receptor de LH, aumento da expressão do receptor de andrógenos testiculares e epididimais. O tratamento com T3 acarretou a diminuição do mRNA e aumento do conteúdo protéico de LH, aumento do FSH sérico, diminuição do conteúdo do mRNA e aumento do conteúdo protéico do FSH, aumento da expressão do receptor de LH, redução da expressão de receptores de andrógenos testiculares e epididimais. Esses resultados sugerem que o T3 age na modulação da função do gonadotrofo e na modulação da expressão dos receptores em tecidos-alvo. / Reproductive disorders occur in hypo and hyperthyroidism, but little is known about the molecular basis of these alterations. The effect of administration of triiodothyronine (T3) on the activity of gonadotropes in thyroidectomyzed male Wistar rats was evaluated. Hypothyroidism caused increased on TSH and LH serum concentrations, increased of mRNA content and decreased in protein content of LH and FSH, reduction in the length of poli(A) tail of LH, reduction in testosterone and FSH serum concentrations, reduction in the expression of LH receptor, increased in the expression of androgen receptors in the testis and epididymis. T3 treatment caused reduction on mRNA and increased on mRNA of LH and FSH, increased serum FSH, increased the expression of LH receptor, and reduction of the expression of androgen receptors in the testis and epididymis. These results suggest that T3 modulates the function of gonadotrope and the expression of the receptors in target-tissues.

"Circulating tumor cells (CTCs) are cells released into the bloodstream from primary tumors and are suspected to be one of the main causes behind metastatic spreading of cancer. The ability to capture and analyze circulating tumor cells in clinical samples is of great interest in prevailing patient prognosis and clinical management of cancer. Carbon nanotubes, individual rolled-up graphene sheets, have emerged as exciting materials for probing the biomolecular interactions. With diameter of about 1 nm, they can attach themselves to cell surface receptors through specific antibodies and hold a great potential for diagnostic cellular profiling. Carbon nanotubes can be either semiconducting or metallic, and the electronic properties of either type rivals the best known materials. Small size of nanotubes and the ability to functionalize their surface using 1-Pyrenebutanoic Acid, Succinimidyl Ester (PASE), enables a versatile probe for developing a platform for capture and analysis of cancer biomarkers and circulating tumor cells. Although nanotubes have previously been used to electrically detect a variety of molecules and proteins, here for the first time we demonstrate the label free capture of spiked breast cancer cells using ultra-thin carbon nanotube film micro-array devices in a drop of buffy coat and blood. A new statistical approach of using Dynamic Time Warping (DTW) was used to classify the electrical signatures with 90% sensitivity and 90% specificity in blood. These results suggest such label free devices could potentially be useful for clinical capture and further analysis of circulating tumor cells. This thesis will go in-depth the properties of carbon nanotubes, device fabrication and characterization methodologies, functionalization protocols, and experiments in buffy coats and in blood. Combination of nano and biological materials, functionalization protocols and advanced statistical classifiers can potentially enable clinical translation of such devices in the future. "

O câncer cervical é o terceiro tipo de câncer mais comum entre as mulheres, sendo a infecção por HPV16 o principal fator de risco para sua etiopatogênese. Neste trabalho avaliamos o potencial profilático e terapêutico da vacina proteica E6E7, constituída de epítopos imunogênicos de E6 e E7 do HPV16, com ou sem Ubiquitina (Ub) fusionada (E6E7Ub e UbE6E7), contra tumor de células TC-1. A vacina E6E7 conferiu total proteção contra a formação de tumores em animais C57BL/6 selvagens, CD4 nocautes e TLR4 deficientes previamente imunizados e posteriormente desafiados com células TC-1. Entretanto, em animais imunizados após desafio, a fusão da Ub no antígeno E6E7 foi crucial para a vacina promover a regressão do tumor em 60% dos animais. Além da fusão da Ub na extremidade N-terminal do antígeno (UbE6E7) aumentar a poliubiquitinação in vitro, essa estratégia de fusão promoveu uma melhor resposta imunoterapêutica contra o tumor que E6E7 e E6E7Ub, sendo promissora para o desenvolvimento de vacinas terapêuticas contra câncer cervical e também contra outros tipos de câncer. / Cervical cancer is the third most common cancer women worldwide and HPV16 infection is a major risk factor for its ethiopathogenesis. In this study we evaluated in mice the prophylactic and therapeutic potential of the E6E7 proteic vaccine, consisting of immunogenic HPV16 E6 and E7 epitopes, with or without Ubiquitin-fused (E6E7Ub and UbE6E7), against TC-1 tumor cells. The E6E7 vaccine conferred complete protection against tumor growth in previously immunized wild-type, CD4 knockout and TLR4 deficient mice challenged with TC-1 cells. However, immunization of previously challenged animals with TC-1 cells, Ubiquitin-fused antigens promoted tumor regression in 60% of mice against 0% in non-Ubiquitinfused antigens. Besides, the fusion of Ubiquitin at the N-terminus of the antigen (UbE6E7) seems to enhance polyubiquitination in vitro, this Ubiquitin fusion strategy promoted an effective immunotherapeutic response against the tumor, being promising for the development of therapeutic cervical cancer vaccines and also other types of tumor.

O carcinoma tiroidiano apresenta alterações na via MAPK, destacando-se o rearranjo RET/PTC. Alterações na expressão de microRNAs também são observadas. O aumento da expressão de miR-21 nos levou a analisar o papel deste na tumorigênese tiroidiana, bem como a influência da ativação oncogênica de RET/PTC3 durante este processo. A expressão de miR-21 foi analisada em 4 linhagens e a sua modulação foi realizada em células PCCL3 e KTC-2. RET/PTC3 foi ativado em células PTC3-5 e analisou-se a sua influência na expressão de miR-21 e na proliferação celular. Todas as linhagens expressam miR-21. A transfecção de anti-miR-21 em células KTC-2 inibiu em 80% a expressão deste miRNA, observando-se um aumento de SMAD7. A super-expressão de miR-21 em PCCL3 não alterou a proliferação. A indução de RET/PTC3 aumentou a expressão de miR-21 e diminui a proliferação, e quando ativado concomitante ao tratamento com TGFb-1, a diminuição na proliferação se acentuou, sugerindo que RET/PTC3 ative a via TGFb através da inibição de SMAD7 mediada por miR-21. / Alterations in MAPK signaling are common in thyroid cancer, including RET/PTC rearrangement. Additionally, several studies described the altered expression of microRNAs. The up-regulation of miR-21 on thyroid cancer led us to evaluate the role of this molecule on thyroid tumorigenesis, and also the influence of RET/PTC3 activation in this process. MiR-21 expression was analyzed in four thyroid cell lines, and the modulation of this miRNA was performed in KTC-2 and PCCL3 cells. PTC3-5 cells were used to analyze the influence of RET/PTC3 on miR-21 expression and cell proliferation. miR-21 expression was found in both cell lines. Anti-miR-21 transfection in KTC-2 cells decreased miR-21 levels in 80% and also increased SMAD7 expression. The up-regularion of RET/PTC3 increased miR-21 expression and decreased cell growth. The activation of RET/PTC3 combined to TGFb-1 treatment accentuated decrease in proliferation, suggesting that RET/PTC3 positively regulates TGFb pathway through miR-21-dependent SMAD7 inhibition.

Introduction:Un des problèmes du cancer du Pancréas (CP) est le temps de latence entre la suspicion du CP et la mise en place des traitements. Les méthodes de biopsie liquide pourraient accélérer la mise en évidence d’éléments tumoraux et le diagnostic.Objectif :L’objectif principal de l’étude était de comparer la performance diagnostique de plusieurs techniques de biopsie liquide chez des patients atteint d’un CP résécable d’emblé. L’objectif secondaire était la corrélation avec le taux de récidive post-opératoire.Méthodes:Tout d'abord, nous avons testé 2 méthodes d'enrichissement CTC pour estimer la sensibilité de la détection CTC avec des expériences de cell-spiking de deux lignées de cellules tumorales pancréatiques dans des échantillons de sang de 24 volontaires sains en utilisant la méthode en gradient de densité OncoQuick® et la méthode de sélection négative RosetteSep™. De plus, les mutations KRAS ont été quantifiées dans l'ADN génomique de cellules purifiées par digital droplet PCR (dd-PCR) avec des amorces spécifiques des allèles.Nous avons conçu un essai clinique prospectif (NCT03032913) visant à détecter les cellules tumorales circulantes (CTC), l’ADN tumoral circulant (ADNct) et les onco-exosomes chez les patients atteint de CP et chez les patients d’un groupe témoin. Pour les CTCs : enrichissement et détection de CTCs par la méthode CellSearch©, méthode d’enrichissement de CTCs RosetteSep® et OncoQuick® puis quantification de l’ADN tumoral par dd-PCR. Les exosomes ont été isolés puis caractérisés avec le taux d’expression de Glypican-1. Tous les patients de l’étude ont eu un prélèvement de sang périphérique, les patients du groupe CP ont eu un prélèvement de sang portal peropératoire.Résultats:La sensibilité analytique était de 100 % pour OncoQuick®, quelle que soit la lignée cellulaire, et se situait entre 70 et 100 % pour RosetteSep™. Le taux moyen de récupération des cellules était de 56±23% pour OncoQuick® contre 39±27% pour RosetteSep™ (p<0,001). Les cellules tumorales de la population de cellules sanguines enrichies ont été détectées par dd-PCR après enrichissement par RosetteSep™ et OncoQuick® La détection des allèles K-RAS mutants par ddPCR après enrichissement de RosetteSepTM était 3 à 4 fois plus sensible qu'après OncoQuick®. Ainsi, RosetteSep™ est plus fiable en termes d'efficacité de récupération et de détection des mutants KRAS que OncoQuick®.De février à novembre 2017, 22 patients atteints de CP résécable et 28 patients témoins ont été inclus. Tous les patients ont été détectés positifs par au moins une méthode. Les CTCs ont été détectées chez 9 patients avec la méthode cellsearch (70% dans le sang portal exclusif) et 13 avec la méthode Rosettesep (60%). Les onco-exosomes ont été détecté chez 14 patients sur 22. L’ADNct n’a été détecté que chez deux patients métastatiques. La détection combinée des CTCs et des onco-exosomes était significativement corrélée à la survie sans récidive.Conclusion:Cette étude suggère que la biopsie liquide combinée peut être un outil prometteur à fois diagnostique et pronostique dans le CP à un stade précoce. / Introduction:One of the problems of pancreatic ductal adenocarcinoma (PC) is the latency time between the suspicion of PC and the initiation of treatments, especially neo-adjuvants that require histological evidence. Liquid biopsy methods could be a companion test for diagnosis.Objective :The main objective of the study was to compare the diagnostic performance of several liquid biopsy techniques in patients with resectable pancreatic without neo-adjuvant therapy cancer. The secondary objective was the correlation between the quantification of liquid biopsy parameters and clinic-pathologic features.Methods:First, we tested 2 CTC enrichment methods to estimate the sensitivity of CTC detection with cell spiking experiments of two pancreatic tumour cell lines in blood samples from 24 healthy volunteers using the onco-specific density gradient OncoQuick® and the negative selection enrichment method RosetteSep™. Additionally, KRAS mutations were quantified in genomic DNA of purified cells by digital droplet Q-PCR (dd-PCR) with allele specific primers.We designed a prospective clinical trial (PANC-CTC# NCT03032913) to detect circulating tumour cells (CTC), circulating tumour DNA (ADNct) and onco-exosomes in patients with pancreatic cancer and in patients in a control group using different methods. For CTCs, it was the enrichment and detection of CTCs by the CellSearch© method (reference method), the RosetteSep® and OncoQuick® CTC enrichment method and the quantification of tumor DNA by dd-PCR. Exosomes were isolated and characterized with the expression rate of Glypican-1. All patients in the study had a peripheral blood sample, patients in the PDAC group had a portal blood sample during surgery.Results:Analytical sensitivity was 100% for OncoQuick®, regardless of the cell line, and ranged between 70 and 100% for RosetteSep™. Mean recovery rate of cells was 56±23% for OncoQuick® versus 39±27% for RosetteSep™ (p<0.001). Molecular detection of mutant K-RAS alleles by ddPCR after RosetteSepTM enrichment was 3- to 4-fold more sensitive than after OncoQuick®. Thus, RosetteSep™ is more reliable in terms of recovery efficiency and KRAS mutant detection than OncoQuick®.From February to November 2017, 22 patients with resectable pancreatic cancer and 28 control patients were included. All patients were positive by at least one method. CTCs were detected in 9 patients with the cellsearch method (70% in the exclusive portal blood) and 13 with the Rosettesep method (59%), Onco-exosomes were detected in 14 out of 22(64%) patients in peripheral and/or portal blood. DNAct was detected in only two metastatic patients. The combined detection of CTCs with cellsearch and onco-exosomes was significantly correlated with progression free survival and overall survival when CTC cluster were found.Conclusion: This study suggests that combined liquid biopsy can be a promising tool for both diagnosis and prognosis in early pancreatic cancer.

Diss. (sammanfattning) Umeå : Univ., 2003. / Härtill 4 uppsatser.

Thesis (Ph. D.)--Medical College of Ohio, 2004. / "In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Medical Sciences." Major advisor: Manohar Ratnam. Includes abstract. Document formatted into pages: iii, 293 p. Title from title page of PDF document. Includes bibliographical references (p. 175-281).